362 related articles for article (PubMed ID: 26147141)
21. CMV specific T cell immunity predicts early viremia after liver transplantation.
Shin KH; Lee HJ; Chang CL; Kim EJ; Lim S; Lee SJ; Ryu JH; Yang K; Choi BH; Lee TB; Lee SM
Transpl Immunol; 2018 Dec; 51():62-65. PubMed ID: 30243982
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant.
Kim T; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
Korean J Intern Med; 2020 Mar; 35(2):438-448. PubMed ID: 29865778
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
24. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
[TBL] [Abstract][Full Text] [Related]
25. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.
Banas B; Böger CA; Lückhoff G; Krüger B; Barabas S; Batzilla J; Schemmerer M; Köstler J; Bendfeldt H; Rascle A; Wagner R; Deml L; Leicht J; Krämer BK
BMC Immunol; 2017 Mar; 18(1):15. PubMed ID: 28270092
[TBL] [Abstract][Full Text] [Related]
26. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
Barron MA; Gao D; Springer KL; Patterson JA; Brunvand MW; McSweeney PA; Zeng C; Barón AE; Weinberg A
Clin Infect Dis; 2009 Dec; 49(12):1777-83. PubMed ID: 19911937
[TBL] [Abstract][Full Text] [Related]
27. IgM antibody detection of ppUL80A and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients.
Kraat YJ; Stals FS; Christiaans MH; Lazzarotto T; Landini MP; Bruggeman CA
J Med Virol; 1996 Mar; 48(3):289-94. PubMed ID: 8801292
[TBL] [Abstract][Full Text] [Related]
28. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.
Lochmanova A; Lochman I; Tomaskova H; Marsalkova P; Raszka J; Mrazek J; Dedochova J; Martinek A; Brozmanova H; Grundmann M
Transplant Proc; 2010 Nov; 42(9):3574-7. PubMed ID: 21094818
[TBL] [Abstract][Full Text] [Related]
29. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
Schachtner T; Stein M; Reinke P
Transplantation; 2017 Oct; 101(10):e315-e325. PubMed ID: 28594749
[TBL] [Abstract][Full Text] [Related]
30. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study.
Sund F; Lidehäll AK; Claesson K; Foss A; Tötterman TH; Korsgren O; Eriksson BM
Clin Transplant; 2010; 24(3):401-9. PubMed ID: 19222507
[TBL] [Abstract][Full Text] [Related]
31. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
32. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.
Fernández-Ruiz M; Giménez E; Vinuesa V; Ruiz-Merlo T; Parra P; Amat P; Montejo M; Paez-Vega A; Cantisán S; Torre-Cisneros J; Fortún J; Andrés A; San Juan R; López-Medrano F; Navarro D; Aguado JM;
Clin Microbiol Infect; 2019 Mar; 25(3):381.e1-381.e10. PubMed ID: 29803844
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.
Christmas SE; Halliday D; Lawton N; Wang H; Abdalla I; Masters J; Hassan RL; Hart IJ; Khan N; Smith J; Hammad A; Bakran A
Transpl Immunol; 2009 Dec; 22(1-2):99-104. PubMed ID: 19635559
[TBL] [Abstract][Full Text] [Related]
34. CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy.
Mena-Romo JD; Pérez Romero P; Martín-Gandul C; Gentil MÁ; Suárez-Artacho G; Lage E; Sánchez M; Cordero E
J Infect; 2017 Oct; 75(4):336-345. PubMed ID: 28599954
[TBL] [Abstract][Full Text] [Related]
35. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
Sarmiento E; Lanio N; Gallego A; Rodriguez-Molina J; Navarro J; Fernandez-Yañez J; Palomo J; Rodríguez-Hernández C; Ruiz M; Alonso R; Fernandez-Cruz E; Carbone J
Int Immunopharmacol; 2009 Jun; 9(6):649-52. PubMed ID: 18940269
[TBL] [Abstract][Full Text] [Related]
36. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
[TBL] [Abstract][Full Text] [Related]
37. Surveillance of γδ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants.
Kaminski H; Garrigue I; Couzi L; Taton B; Bachelet T; Moreau JF; Déchanet-Merville J; Thiébaut R; Merville P
J Am Soc Nephrol; 2016 Feb; 27(2):637-45. PubMed ID: 26054538
[TBL] [Abstract][Full Text] [Related]
38. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
[TBL] [Abstract][Full Text] [Related]
39. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
Tarasewicz A; Dębska-Ślizień A; Rutkowski B
Transplant Proc; 2016 Jun; 48(5):1650-3. PubMed ID: 27496465
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of viral load and antigenemia as markers for relapse cytomegalovirus infection in renal transplant recipients].
Franco A; Serrano R; Gimeno A; de Juan J; Merino E; Jiménez del Cerro L; Olivares J
Nefrologia; 2007; 27(2):202-8. PubMed ID: 17564566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]